An Phase Ib/II Clinical Trial of TCC1727 Combination Therapy in Advanced Solid Tumors

This is a Phase Ib/II clinical study. The Phase Ib dose-escalation study aims to evaluate and determine the recommended Phase II dose (RP2D) of TCC1727 in combination with benmelstobart /olaparib /topotecanfor patients with advanced solid tumors. The Phase II expansion study will assess the efficacy and safety of TCC1727 combined with benmelstobart /olaparib/topotecanin selected advanced solid tumor indications. The study pre-specifies three treatment combinations, with Combination 1 (TCC1727 + benmelstobart) being prioritized for initial evaluation. The decision to proceed with Combination

Trial Details

NCT ID
NCT07371663
Phase
PHASE1 / PHASE2
Sponsor
Beijing Tide Pharmaceutical Co., Ltd
Status
RECRUITING
Cancer Type
Small Cell (SCLC) Lung Cancer
Locations (sample)
  • Beijing, Beijing Municipality, China|39.9075,116.39723
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

  • -Voluntarily participate in this study and sign the informed consent form.
  • At the time of signing the informed consent, subjects must be ≥18 years of age (inclusive).
  • Subjects must have histologically or cytologically confirmed advanced or metastatic solid tumors and have experienced disease progression following…
  • Phase Ib :Subjects with advanced, recurrent, or refractory solid tumors, which may include (but are not limited to) the specific tumor types in Pha…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Small Cell (SCLC) Lung Cancer Trials on Trialify →